Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PET study of sembragiline (RG1577) in Japanese patients with Alzheimer's disease
jRCT2080222554Phase 1
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sembragiline in Alzheimer's disease (AD), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
sembragiline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080222554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222554.